NextCure’s treatment of osteogenesis imperfecta was granted orphan designation by the FDA, according to a post to the agency’s website.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXTC:
- NextCure reports Q1 EPS (61c), consensus (46c)
- NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024